Document Detail

Pemetrexed: single-agent and combination phase I study overview.
MedLine Citation:
PMID:  12571806     Owner:  NLM     Status:  MEDLINE    
Pemetrexed is a novel folic acid antimetabolite that exerts its activity by the inhibition of multiple enzyme targets. It has been evaluated in a series of phase I clinical trials that explored different administration schedules. The schedule that has been carried forward into phase II trials involves the administration of pemetrexed as a 10-minute intravenous infusion every 21 days with no standard pretreatment with folic acid or vitamin B(12). When given in this manner, the dose-limiting toxicities were neutropenia and thrombocytopenia. Other toxicities included mucositis, rash, and fatigue. The recommended phase II dose was 600 mg/m(2) administered intravenous every 21 days, although this was subsequently modified to 500 mg/m(2) when several early patients experienced toxicities requiring dose reduction in phase II studies. On the basis of preclinical studies suggesting additive or synergistic effects, pemetrexed has also been evaluated in phase I studies in combination with several other agents including cisplatin, carboplatin, oxaliplatin, irinotecan, the taxanes, and anthracyclines. Encouraging anticancer activity has been observed in many of these studies.
Michael J Boyer; Laurent P Rivory; Stephen J Clarke
Related Documents :
10673536 - Phase i and pharmacokinetic study of farnesyl protein transferase inhibitor r115777 in ...
18381956 - Dts-108, a novel peptidic prodrug of sn38: in vivo efficacy and toxicokinetic studies.
10811676 - Phase i pharmacologic study of oral topotecan and intravenous cisplatin: sequence-depen...
12490776 - Allopurinol for the treatment of aggressive behaviour in patients with dementia.
1887556 - Pharmacokinetics and pharmacodynamics of piroxicam in dogs.
3690046 - The clonidine test for the diagnosis of pheochromocytoma: the usefulness of urinary met...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in oncology     Volume:  29     ISSN:  0093-7754     ISO Abbreviation:  Semin. Oncol.     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2003-02-06     Completed Date:  2003-03-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0420432     Medline TA:  Semin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  18-23     Citation Subset:  IM    
Copyright Information:
Copyright 2002, Elsevier Science (USA). All rights reserved.
Department of Medical Oncology, Sydney Cancer Centre, Camperdown, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Clinical Trials, Phase I as Topic
Folic Acid Antagonists / therapeutic use*
Glutamates / administration & dosage,  therapeutic use*
Guanine / administration & dosage,  analogs & derivatives*,  therapeutic use*
Neoplasm Recurrence, Local / drug therapy*
Thymidylate Synthase / antagonists & inhibitors*
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Folic Acid Antagonists; 0/Glutamates; 137281-23-3/pemetrexed; 73-40-5/Guanine; EC Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular, biochemical, and cellular pharmacology of pemetrexed.
Next Document:  Pemetrexed safety and dosing strategy.